Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125865441 | 12586544 | 1 | I | 20160511 | 0 | 20160722 | 20160722 | DIR | 73.00 | YR | M | N | 101.60000 | KG | 20160720 | N | PH | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125865441 | 12586544 | 1 | PS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | Oral | Y | D | 0 | 500 | MG | BID | ||||||
| 125865441 | 12586544 | 2 | SS | METRONIDAZOLE. | METRONIDAZOLE | 1 | Oral | Y | D | 0 | 500 | MG | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125865441 | 12586544 | 1 | Hypersensitivity |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125865441 | 12586544 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125865441 | 12586544 | Fatigue | |
| 125865441 | 12586544 | Pyrexia | |
| 125865441 | 12586544 | Rash |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 125865441 | 12586544 | HP |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125865441 | 12586544 | 1 | 20160509 | 20160512 | 0 | |
| 125865441 | 12586544 | 2 | 20160509 | 20160512 | 0 |